We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00272727
First Posted: January 9, 2006
Last Update Posted: January 24, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The purpose of the study is to assess if a dialog tool can improve compliance and asthma control in patients with asthma.

Condition Intervention
Asthma Behavioral: Dialog tool for caregivers

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • ACQ

Secondary Outcome Measures:
  • Ability to follow prescription, AQLQ, lung function, No, eosinophil

Estimated Enrollment: 100
Study Start Date: February 2006
Study Completion Date: May 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of asthma >/= 3 months,
  • Prescribed daily use of inhaled glucocorticosteroid

Exclusion Criteria:

  • Asthma exacerbation within the last month
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00272727


Locations
Denmark
Research Site
Copenhagen, Denmark
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca Denmark Medical Director, MD AstraZeneca
  More Information

ClinicalTrials.gov Identifier: NCT00272727     History of Changes
Other Study ID Numbers: NIS-RDK-DUM-2005/1
AZ-SOREN
First Submitted: January 4, 2006
First Posted: January 9, 2006
Last Update Posted: January 24, 2011
Last Verified: January 2011

Keywords provided by AstraZeneca:
Asthma
dialog tool
compliance